Modern BioPharma Podcast
ATMPs...or Advanced Therapeutic Medicinal Products, are the "next big thing" in the world of #Pharma. If you are in the space, the big ones you hear most about are Cell & Gene Therapy and...lately...mRNA vaccines (thank you COVID-19). This world isn't as simple as 2 or 3 therapies...it's more than that. Investment in Cell&Gene Therapy has been setting records with $20 and $23 Billion in the last 2 years alone. This is kind of a big deal. Jake Adams, from CRB [https://www.crbgroup.com/], joins me to discuss this and also the world of #RNA modulating therapies (not all as well known as mRNA Vaccines). We discuss what makes these different therapies unique, what makes them effective, and more. Also a few rabbit trails including how did Jake turn into a go-to man for RNA as a young engineer. So listen up... :) Check at Jake on LinkedIn [https://www.linkedin.com/in/jake-adams-27620349/]! Subscribe to our channel [https://www.youtube.com/c/ModernBiopharmaPodcast]! Want to learn more about investment into the Cell & Gene Space? CGT 2022 Investment Outlook [https://www.cellandgene.com/doc/cell-gene-therapies-investment-outlook-in-beyond-0001#:~:text=Early%20Approvals%20Pave%20The%20Way%20For%20New%20Market%20Entrants&text=The%20number%20of%20approved%20treatments,are%20cord%20blood%2Dbased%20treatments] Learn about Oligonucleotides HERE [https://www.certara.com/blog/maximizing-oligonucleotide-therapeutic-development-how-they-work/]! Quick overview about TPDs HERE! [https://www.eurekaselect.com/article/105757]
33 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity Modern BioPharma Podcast-yhteisöön!